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Heart failure is a complex disorder, characterized by activation of the sympathetic nervous system, leading
to dysregulated Ca2+ homeostasis in cardiac myocytes and tissue remodeling. In a variety of diseases, cardiac
malfunction is associated with aberrant fluxes of Ca2+ across both the surface membrane and the internal Ca2+
store, the sarcoplasmic reticulum (SR). One prominent hypothesis residues is that in heart failure, the activity of
the ryanodine receptor (RyR2) Ca2+ release channel in the SR is increased due to excess phosphorylation and
that this contributes to excess SR Ca2+ leak in diastole, reduced SR Ca2+ load and decreased contractility (Huke
& Bers, 2008). There is controversy over which serine residues in RyR2 are hyperphosphorylated in animal
models of heart failure and whether this is via the CaMKII or the PKA-linked signaling pathway. S2808, S2814
and S2030 in RyR2 have been variously claimed to be hyperphosphorylated. Our aim was to examine the degree
of phosphorylation of these residues in RyR2 from failing human hearts.
The use of human tissue was approved by the Human Research Ethics Committee, The Prince Charles
Hospital, EC28114. Left ventricular tissue samples were obtained from an explanted heart of a patient with end-
stage heart failure (Emery Dreifuss Muscular Dystrophy with cardiomyopathy) and non-failing tissue was from
a patient with cystic fibrosis undergoing heart-lung transplantation with no history of heart disease. SR vesicles
were prepared as described by Laver et al. (1995) and examined with SDS-Page and Western Blot. Transferred
proteins were probed with antibodies to detect total protein phosphorylation, phosphorylation of RyR2 serine
residues S2808, S2814, S2030 and for the key proteins calsequestrin, triadin, junctin and FKBP12.6. To avoid
membrane stripping artifact, each membrane was exposed to one phosphorylation-specific antibody and signal
densities quantified using Bio-Rad Quantity One software.
We found no distinguishable difference between failing and healthy hearts in the protein expression levels
of RyR2, triadin, junctin or calsequestrin. We found an expected upregulation of total RyR2 phosphorylation in
the failing heart sample, compared to a matched amount of RyR2 (quantified using densiometry) in healthy
heart. Probing with antibodies detecting only the phosphorylated form of the specific RyR2 residues showed that
the increase in total RyR2 phosphorylation in the failing heart was due to hyperphosphorylation of S2808 and
S2814. We found that S2030 phosphorylation levels were unchanged in human heart failure. Interestingly, we
found that S2030 has a basal level of phosphorylation in the healthy human heart, different from the absence of
basal phosphorylation recently reported in rodent heart (Huke & Bers, 2008). Finally, preliminary results
indicate that less FKBP 12.6 is associated with RyR2 in the failing heart, possibly as a consequence of PKA
activation.
In conclusion, residues S2808 and S2814 are hyperphosphorylated in human heart failure, presumably
due to upregulation of the CaMKII and/or PKA signaling pathway as a result of chronic activation of the
sympathetic nervous system. Such changes in RyR2 phosphorylation are believed to contribute to the leaky
RyR2 phenotype associated with heart failure, which increases the incidence of arrhythmia and contributes to
the severely impaired contractile performance of the failing heart.
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